<DOC>
	<DOCNO>NCT02976038</DOCNO>
	<brief_summary>This Phase 2 Open-Label extension study evaluate long term safety tolerability daily elamipretide injection patient genetically confirm Primary Mitochondrial Disease previously participate SPIMM-202 Clinical Trial</brief_summary>
	<brief_title>Open-Label Extension Trial Characterize Long-term Safety Tolerability Elamipretide Subjects With Genetically Confirmed Primary Mitochondrial Disease ( PMD )</brief_title>
	<detailed_description>This open-label , non-comparative , extension trial enroll subject genetically confirm PMD complete End-of-Study Visit SPIMM-202 trial . Subjects discontinue withdraw trial receive treatment 40 mg SC elamipretide shortest follow : 260 week ; regulatory approval commercial availability elamipretide subject 's respective country ; termination clinical development elamipretide subject PMD .</detailed_description>
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<criteria>Investigator determines subject , subject agrees , adhere trial requirement length trial include selfadministration ( subject train caregiver ) study drug Subject complete EndofStudy Visit SPIMM202 Subject prior current medical condition , judgment Investigator , would prevent subject safely participate and/or complete trial requirement Subject receive investigational compound ( exclude elamipretide ) and/or participate another interventional clinical trial within 30 day prior SPIMM203 Baseline Visit ( exclude SPIMM202 ) concurrently enrol noninterventional research type judge scientifically medically incompatible trial deem Investigator consultation Sponsor Subject experience adverse reaction attribute study drug result permanent discontinuation study drug SPIMM202 trial . Female subject pregnant , plan become pregnant , lactate Subject undergone inpatient hospitalization within 1 month prior SPIMM203 Baseline Visit</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Primary Mitochondrial Disease</keyword>
	<keyword>Stealth</keyword>
	<keyword>elamipretide</keyword>
</DOC>